Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Non-cash Items (2019 - 2022)

Historic Non-cash Items for Nurix Therapeutics (NRIX) over the last 4 years, with Q3 2022 value amounting to $85.9 million.

  • Nurix Therapeutics' Non-cash Items rose 5646.63% to $85.9 million in Q3 2022 from the same period last year, while for Aug 2022 it was $85.9 million, marking a year-over-year increase of 5646.63%. This contributed to the annual value of $57.9 million for FY2021, which is 5900.86% down from last year.
  • Per Nurix Therapeutics' latest filing, its Non-cash Items stood at $85.9 million for Q3 2022, which was up 5646.63% from $68.2 million recorded in Q2 2022.
  • Over the past 5 years, Nurix Therapeutics' Non-cash Items peaked at $141.2 million during Q4 2020, and registered a low of $762000.0 during Q4 2019.
  • Its 4-year average for Non-cash Items is $59.5 million, with a median of $56.4 million in 2021.
  • Its Non-cash Items has fluctuated over the past 5 years, first skyrocketed by 1843661.42% in 2020, then plummeted by 5900.86% in 2021.
  • Quarter analysis of 4 years shows Nurix Therapeutics' Non-cash Items stood at $762000.0 in 2019, then skyrocketed by 18436.61% to $141.2 million in 2020, then crashed by 59.01% to $57.9 million in 2021, then surged by 48.36% to $85.9 million in 2022.
  • Its Non-cash Items stands at $85.9 million for Q3 2022, versus $68.2 million for Q2 2022 and $75.2 million for Q1 2022.